(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are AGBA Acquisition Limited, Aclaris Therapeutics, and Senmiao Technology Limited.

The three biggest losers today are Allakos, Brooge Energy Limited , and ASLAN Pharmaceuticals Limited.

Winners today

1. AGBA Acquisition Limited (AGBAW) – 266.67%

AGBA Group Holding Limited focuses on operating a full-service platform to banks, other financial institutions, brokers, and individual financial advisors to advise and serve its retail clients. The company offers a range of financial products, such as life insurance, pensions, property-casualty insurance, mutual funds, money lending, and real estate agency services. It also operates an health and wealth management platform that offers a range of services and value-added information in health, insurance, investments, and social sharing. The company is based in Wan Chai, Wan Chai.

NASDAQ ended the session with AGBA Acquisition Limited jumping 266.67% to $0.02 on Wednesday while NASDAQ fell 0.59% to $14,855.62.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -10969.8%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 0.3%, now sitting on 53.32M for the twelve trailing months.

Yearly Top and Bottom Value

AGBA Acquisition Limited’s stock is valued at $0.02 at 16:32 EST, higher than its 52-week high of $0.02.

More news about AGBA Acquisition Limited.

2. Aclaris Therapeutics (ACRS) – 25.54%

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound, which is being developed as a treatment for moderate to severe rheumatoid arthritis and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is being developed as a treatment for moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound, which is being developed as a treatment for psoriasis and/or inflammatory bowel disease. It also provides contract research services. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

NASDAQ ended the session with Aclaris Therapeutics jumping 25.54% to $1.16 on Wednesday while NASDAQ fell 0.59% to $14,855.62.

Earnings Per Share

As for profitability, Aclaris Therapeutics has a trailing twelve months EPS of $-1.66.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -60.94%.

Volume

Today’s last reported volume for Aclaris Therapeutics is 6037510 which is 18.33% above its average volume of 5101920.

Revenue Growth

Year-on-year quarterly revenue growth declined by 51.2%, now sitting on 21.43M for the twelve trailing months.

Sales Growth

Aclaris Therapeutics’s sales growth for the current quarter is negative 56.7%.

Yearly Top and Bottom Value

Aclaris Therapeutics’s stock is valued at $1.16 at 16:32 EST, way under its 52-week high of $18.54 and way higher than its 52-week low of $0.59.

More news about Aclaris Therapeutics.

3. Senmiao Technology Limited (AIHS) – 13.67%

Senmiao Technology Limited engages in the automobile transaction and related services business in the People's Republic of China. Its services include the facilitation of automobile transaction and financing, connecting ride-hailing drivers to financial institutions to buy, or get financing on the purchase of, cars to be used to provide ride-hailing services. The company is also involved in the sale of automobiles; and provision of auto finance services. Senmiao Technology has strategic cooperation with Gaode Map for utilization in ride sharing initiatives. Senmiao Technology Limited was incorporated in 2017 and is based in Chengdu, the People's Republic of China.

NASDAQ ended the session with Senmiao Technology Limited jumping 13.67% to $0.49 on Wednesday while NASDAQ fell 0.59% to $14,855.62.

Earnings Per Share

As for profitability, Senmiao Technology Limited has a trailing twelve months EPS of $-0.49.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -51.76%.

More news about Senmiao Technology Limited.

4. Aileron Therapeutics (ALRN) – 13.38%

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. Aileron Therapeutics, Inc. has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.

NASDAQ ended the session with Aileron Therapeutics jumping 13.38% to $4.49 on Wednesday, after two successive sessions in a row of gains. NASDAQ fell 0.59% to $14,855.62, following the last session’s downward trend on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, Aileron Therapeutics has a trailing twelve months EPS of $-2.85.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -76.36%.

More news about Aileron Therapeutics.

5. AYRO (AYRO) – 9.43%

Ayro, Inc. designs and manufactures light-duty, emissions-free electric vehicles for urban and community transport, local delivery, closed campus mobility, recreational, and government use. It offers AYRO 311, a 3-wheeled vehicle for professional and personal use; Club Car 411 for low-speed logistics and cargo services for campus; and AYRO 511 4×4 concepts. The company was formerly known as AEV Technologies, Inc. Ayro, Inc. was founded in 2017 and is headquartered in Round Rock, Texas.

NASDAQ ended the session with AYRO rising 9.43% to $1.74 on Wednesday, following the last session’s upward trend. NASDAQ fell 0.59% to $14,855.62, following the last session’s downward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, AYRO has a trailing twelve months EPS of $-6.92.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -65.69%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 76.3%, now sitting on 949.93k for the twelve trailing months.

Moving Average

AYRO’s value is under its 50-day moving average of $1.87 and way below its 200-day moving average of $3.71.

More news about AYRO.

6. Benitec Biopharma (BNTC) – 8.22%

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

NASDAQ ended the session with Benitec Biopharma jumping 8.22% to $3.21 on Wednesday, after two consecutive sessions in a row of losses. NASDAQ fell 0.59% to $14,855.62, following the last session’s downward trend on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, Benitec Biopharma has a trailing twelve months EPS of $-234.82.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -110.63%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Benitec Biopharma’s EBITDA is -0.99.

Volume

Today’s last reported volume for Benitec Biopharma is 379 which is 95.95% below its average volume of 9365.

Moving Average

Benitec Biopharma’s worth is under its 50-day moving average of $3.32 and under its 200-day moving average of $3.41.

More news about Benitec Biopharma.

7. Artelo Biosciences (ARTL) – 7.04%

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences has research collaboration with Trinity College Dublin to Investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was founded in 2011 and is headquartered in La Jolla, California.

NASDAQ ended the session with Artelo Biosciences jumping 7.04% to $1.52 on Wednesday while NASDAQ fell 0.59% to $14,855.62.

Earnings Per Share

As for profitability, Artelo Biosciences has a trailing twelve months EPS of $-3.33.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -52.38%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Artelo Biosciences’s EBITDA is 3.98.

Yearly Top and Bottom Value

Artelo Biosciences’s stock is valued at $1.52 at 16:32 EST, way under its 52-week high of $3.50 and way above its 52-week low of $1.15.

Moving Average

Artelo Biosciences’s worth is way higher than its 50-day moving average of $1.36 and way below its 200-day moving average of $1.74.

More news about Artelo Biosciences.

8. Air T (AIRTP) – 6.11%

Air T, Inc., through its subsidiaries, provides overnight air cargo, ground equipment sale, commercial jet engines and parts, and printing equipment and maintenance services in the United States and internationally. The company's Overnight Air Cargo segment offers air express delivery services. As of March 31, 2021, this segment had 66 aircraft under the dry-lease agreements with FedEx. Its Ground Equipment Sales segment manufactures, sells, and services aircraft deicers, scissor-type lifts, military and civilian decontamination units, flight-line tow tractors, glycol recovery vehicles, and other specialized equipment. This segment sells its products to passenger and cargo airlines, ground handling companies, the United States Air Force, airports, and industrial customers. Its Commercial Aircraft, Engines and Parts segment offers commercial aircraft trading, leasing, and parts solutions; commercial aircraft storage, storage maintenance, and aircraft disassembly/part-out services; commercial aircraft parts sales, exchanges, procurement services, consignment programs, and overhaul and repair services; and aircraft instrumentation, avionics, and a range of electrical accessories for civilian, military transport, regional/commuter and business/commercial jet, and turboprop aircraft. This segment also provides composite aircraft structures, and repair and support services. Air T, Inc. was incorporated in 1980 and is based in Denver, North Carolina.

NASDAQ ended the session with Air T rising 6.11% to $18.92 on Wednesday while NASDAQ slid 0.59% to $14,855.62.

Earnings Per Share

As for profitability, Air T has a trailing twelve months EPS of $0.34.

PE Ratio

Air T has a trailing twelve months price to earnings ratio of 56.31. Meaning, the purchaser of the share is investing $56.31 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.28%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 30.1%, now sitting on 286.17M for the twelve trailing months.

Yearly Top and Bottom Value

Air T’s stock is valued at $18.92 at 16:32 EST, way below its 52-week high of $24.21 and way above its 52-week low of $14.69.

More news about Air T.

9. Aprea Therapeutics (APRE) – 5.8%

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts.

NASDAQ ended the session with Aprea Therapeutics rising 5.8% to $6.02 on Wednesday while NASDAQ slid 0.59% to $14,855.62.

Earnings Per Share

As for profitability, Aprea Therapeutics has a trailing twelve months EPS of $12.31.

PE Ratio

Aprea Therapeutics has a trailing twelve months price to earnings ratio of 0.49. Meaning, the purchaser of the share is investing $0.49 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -51.87%.

Yearly Top and Bottom Value

Aprea Therapeutics’s stock is valued at $6.02 at 16:32 EST, way under its 52-week high of $12.00 and way higher than its 52-week low of $0.47.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 16.3% and 85.1%, respectively.

Moving Average

Aprea Therapeutics’s worth is way above its 50-day moving average of $4.12 and way above its 200-day moving average of $3.90.

More news about Aprea Therapeutics.

10. Annexon (ANNX) – 5%

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barré syndrome; and ANX007, which has completed Phase 1b clinical trials to treat patients with glaucoma. The company's candidates also comprise ANX005 that has completed preclinical trials to treat patients with warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis; ANX007, which has completed preclinical trials for the treatment of geographic atrophy; and ANX009 that has completed preclinical trials for the treatment of systemic autoimmune diseases. The company was founded in 2011 and is headquartered in South San Francisco, California.

NASDAQ ended the session with Annexon rising 5% to $4.41 on Wednesday, following the last session’s upward trend. NASDAQ dropped 0.59% to $14,855.62, following the last session’s downward trend on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Annexon has a trailing twelve months EPS of $-1.81.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -67.43%.

Yearly Top and Bottom Value

Annexon’s stock is valued at $4.41 at 16:32 EST, way under its 52-week high of $7.65 and way above its 52-week low of $1.57.

Volume

Today’s last reported volume for Annexon is 5458420 which is 632.38% above its average volume of 745296.

Moving Average

Annexon’s worth is way above its 50-day moving average of $3.09 and way above its 200-day moving average of $3.35.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Annexon’s EBITDA is 1.03.

More news about Annexon.

Losers Today

1. Allakos (ALLK) – -60.2%

Allakos Inc. operates as a clinical stage biopharmaceutical company. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic esophagitis. The is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. Allakos Inc. was incorporated in 2012 and is headquartered in Redwood City, California.

NASDAQ ended the session with Allakos sliding 60.2% to $1.19 on Wednesday while NASDAQ slid 0.59% to $14,855.62.

Allakos (allk) plummets 60% on ending development of lead drugThe decision to terminate lirentelimab has led Allakos to restructure its business operations to reduce costs. , Devoid of marketed drugs, Allakos is entirely dependent on AK002 for growth prospects.

Earnings Per Share

As for profitability, Allakos has a trailing twelve months EPS of $-1.53.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -58.79%.

Moving Average

Allakos’s worth is way below its 50-day moving average of $2.47 and way under its 200-day moving average of $3.47.

Volume

Today’s last reported volume for Allakos is 30101900 which is 3295.03% above its average volume of 886646.

Previous days news about Allakos

• Is allakos (allk) stock outpacing its medical peers this year?. According to Zacks on Tuesday, 16 January, "Is Allakos Inc. (ALLK Quick QuoteALLK – Free Report) one of those stocks right now? ", "Looking more specifically, Allakos Inc. belongs to the Medical – Biomedical and Genetics industry, a group that includes 523 individual stocks and currently sits at #86 in the Zacks Industry Rank. "

More news about Allakos.

2. Brooge Energy Limited (BROGW) – -59.46%

Brooge Energy Limited, through its subsidiaries, provides oil storage and related services at the Port of Fujairah in the United Arab Emirates. It operates phase I and phase II facilities comprising 22 tanks with a capacity of approximately 1,001,388 cubic meters for offering storage, heating, and blending of fuel oil and clean petroleum products, including aviation fuel, gas oil, gasoline, marine gas oil, and naphtha. The company was formerly known as Brooge Holdings Limited and changed its name to Brooge Energy Limited in April 2020. Brooge Energy Limited was incorporated in 2019 and is headquartered in Dubai, the United Arab Emirates.

NASDAQ ended the session with Brooge Energy Limited falling 59.46% to $0.01 on Wednesday while NASDAQ slid 0.59% to $14,855.62.

Revenue Growth

Year-on-year quarterly revenue growth grew by 121.5%, now sitting on 116.05M for the twelve trailing months.

More news about Brooge Energy Limited .

3. ASLAN Pharmaceuticals Limited (ASLN) – -38.1%

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

NASDAQ ended the session with ASLAN Pharmaceuticals Limited dropping 38.1% to $0.59 on Wednesday, following the last session’s downward trend. NASDAQ fell 0.59% to $14,855.62, following the last session’s downward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, ASLAN Pharmaceuticals Limited has a trailing twelve months EPS of $-3.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -426.64%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 37.5% and 51.2%, respectively.

Earnings Before Interest, Taxes, Depreciation, and Amortization

ASLAN Pharmaceuticals Limited’s EBITDA is -3.31.

Volume

Today’s last reported volume for ASLAN Pharmaceuticals Limited is 780554 which is 362.63% above its average volume of 168721.

More news about ASLAN Pharmaceuticals Limited.

4. Applied UV (AUVI) – -23.36%

Applied UV, Inc. designs, develops, and markets air purification and infection control products in the healthcare, hospitality, commercial, municipal, and residential markets in the United States. The company offers solutions and products in air purification under the Airocide brand and label and disinfection of hard surfaces under the Lumicide brand. It also manufactures and supplies fine decorative framed mirrors, framed art, and vanities. The company is based in Mount Vernon, New York.

NASDAQ ended the session with Applied UV dropping 23.36% to $2.92 on Wednesday, following the last session’s downward trend. NASDAQ dropped 0.59% to $14,855.62, following the last session’s downward trend on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, Applied UV has a trailing twelve months EPS of $182.5.

PE Ratio

Applied UV has a trailing twelve months price to earnings ratio of 0.02. Meaning, the purchaser of the share is investing $0.02 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -80.01%.

Moving Average

Applied UV’s worth is way under its 50-day moving average of $3.26 and way under its 200-day moving average of $27.53.

More news about Applied UV.

5. ATIF Holdings Limited (ATIF) – -19.05%

ATIF Holdings Limited, a consulting company, provides financial consulting services to small and medium-sized enterprises in Asia. It primarily helps clients going public on the OTC markets and exchanges in the United States. The company was incorporated in 2015 and is headquartered in Rancho Cucamonga, California.

NASDAQ ended the session with ATIF Holdings Limited dropping 19.05% to $1.00 on Wednesday, after two successive sessions in a row of losses. NASDAQ slid 0.59% to $14,855.62, following the last session’s downward trend on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, ATIF Holdings Limited has a trailing twelve months EPS of $-0.35.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -130.01%.

Moving Average

ATIF Holdings Limited’s worth is under its 50-day moving average of $1.03 and way below its 200-day moving average of $1.41.

Volume

Today’s last reported volume for ATIF Holdings Limited is 25535 which is 137.09% above its average volume of 10770.

Revenue Growth

Year-on-year quarterly revenue growth declined by 58.3%, now sitting on 2.27M for the twelve trailing months.

More news about ATIF Holdings Limited.

6. ADiTx Therapeutics (ADTX) – -11.39%

ADiTx Therapeutics, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune reprogramming and monitoring. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. ADiTx Therapeutics has a license agreement with Loma Linda University and Leland Stanford Junior University. ADiTx Therapeutics, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.

NASDAQ ended the session with ADiTx Therapeutics sliding 11.39% to $4.59 on Wednesday, after three sequential sessions in a row of losses. NASDAQ fell 0.59% to $14,855.62, following the last session’s downward trend on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, ADiTx Therapeutics has a trailing twelve months EPS of $-12.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -698.6%.

Yearly Top and Bottom Value

ADiTx Therapeutics’s stock is valued at $4.59 at 16:32 EST, way under its 52-week high of $76.40 and way higher than its 52-week low of $3.27.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 91.9% and 93.6%, respectively.

Volume

Today’s last reported volume for ADiTx Therapeutics is 238220 which is 83.02% below its average volume of 1403580.

More news about ADiTx Therapeutics.

7. Avenue Therapeutics (ATXI) – -11.03%

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was incorporated in 2015 and is based in New York, New York.

NASDAQ ended the session with Avenue Therapeutics falling 11.03% to $0.15 on Wednesday, after five sequential sessions in a row of losses. NASDAQ dropped 0.59% to $14,855.62, following the last session’s downward trend on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, Avenue Therapeutics has a trailing twelve months EPS of $-2.62.

Yearly Top and Bottom Value

Avenue Therapeutics’s stock is valued at $0.15 at 16:32 EST, way under its 52-week high of $2.35 and way higher than its 52-week low of $0.13.

More news about Avenue Therapeutics.

8. Aspen Group (ASPU) – -10.86%

Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.

NASDAQ ended the session with Aspen Group falling 10.86% to $0.16 on Wednesday while NASDAQ dropped 0.59% to $14,855.62.

Earnings Per Share

As for profitability, Aspen Group has a trailing twelve months EPS of $-0.38.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.26%.

More news about Aspen Group.

9. Apyx Medical Corporation (APYX) – -10.81%

Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and OEM. It offers electrosurgical generators based on its Helium Plasma Technology for cutting, coagulation, and ablation of soft tissue. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market that allows surgeons to operate with precision and eliminate unintended tissue trauma. It also develops, manufactures, and sells energy generators, disposable hand piece subassemblies, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

NASDAQ ended the session with Apyx Medical Corporation falling 10.81% to $1.98 on Wednesday, after five sequential sessions in a row of losses. NASDAQ slid 0.59% to $14,855.62, following the last session’s downward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, Apyx Medical Corporation has a trailing twelve months EPS of $-0.43.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -40.34%.

More news about Apyx Medical Corporation.

10. AGM Group Holdings (AGMH) – -10.6%

AGM Group Holdings Inc., an integrated technology company, focuses on ASIC chip solutions. Its ASIC chip solutions include chip design, chip research and development, and crypto miner production. It also provides fintech software services. The company offers multi-assets trading and management systems to small and mid-size broker and institutional clients; and interactive trading education website that uses subscription-based method. Its FXSC is an online trading education and social trading network platform for forex traders; and provides trading education to users through interactive trading simulation and trading contests, as well as demo trading services. In addition, the company sells technical support plans; and delivers software customization services. The company was incorporated in 2015 and is based in Wan Chai, Hong Kong.

NASDAQ ended the session with AGM Group Holdings falling 10.6% to $1.56 on Wednesday, following the last session’s downward trend. NASDAQ dropped 0.59% to $14,855.62, following the last session’s downward trend on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, AGM Group Holdings has a trailing twelve months EPS of $0.45.

PE Ratio

AGM Group Holdings has a trailing twelve months price to earnings ratio of 3.47. Meaning, the purchaser of the share is investing $3.47 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 33.17%.

Volume

Today’s last reported volume for AGM Group Holdings is 3441 which is 25.76% below its average volume of 4635.

Yearly Top and Bottom Value

AGM Group Holdings’s stock is valued at $1.56 at 16:32 EST, way below its 52-week high of $2.46 and above its 52-week low of $1.50.

Revenue Growth

Year-on-year quarterly revenue growth declined by 67.8%, now sitting on 165.45M for the twelve trailing months.

Moving Average

AGM Group Holdings’s value is below its 50-day moving average of $1.68 and way below its 200-day moving average of $1.77.

More news about AGM Group Holdings.

Stay up to date with our winners and losers daily report